Treatment of Hemolytic Uremic Syndrome With Eculizumab
Treatment of Hemolytic Uremic Syndrome With Eculizumab
On September 24, 2011, the Food and Drug Administration (FDA) extended the approved indications for eculizumab to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab has been available in the United States since 2007 for the treatment of paroxysmal nocturnal hemoglobinuria. This additional indication makes eculizumab the first drug to be approved for the treatment of aHUS. Recent clinical experience has also suggested that eculizumab may be of benefit in patients with shiga-toxin producing E. coli-induced HUS (STEC-HUS).
Abstract and Introduction
Introduction
On September 24, 2011, the Food and Drug Administration (FDA) extended the approved indications for eculizumab to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab has been available in the United States since 2007 for the treatment of paroxysmal nocturnal hemoglobinuria. This additional indication makes eculizumab the first drug to be approved for the treatment of aHUS. Recent clinical experience has also suggested that eculizumab may be of benefit in patients with shiga-toxin producing E. coli-induced HUS (STEC-HUS).
Source...